One-Year Outcomes After MitraClip for Functional Mitral Regurgitation.
Ailawadi, Gorav MD; Lim, D. Scott MD; Mack, Michael J. MD; Trento, Alfredo MD; Kar, Saibal MD; Grayburn, Paul A. MD; Glower, Donald D. MD; Wang, Andrew MD; Foster, Elyse MD; Qasim, Atif MD; Weissman, Neil J. MD; Ellis, Jeffrey PhD; Crosson, Lori PhD; Fan, Frank MSc; Kron, Irving L. MD; Pearson, Paul J. MD; Feldman, Ted MD; On behalf of the EVEREST II Investigators
139(1):37-47, January 2, 2019.
(Format: HTML, PDF)
Background: Secondary mitral regurgitation (SMR) occurs in the absence of organic mitral valve disease and may develop as the left ventricle dilates or remodels or as a result of leaflet tethering with impaired coaptation, most commonly from apical and lateral distraction of the subvalvular apparatus, with late annular dilatation. The optimal therapy for SMR is unclear. This study sought to evaluate the 1-year adjudicated outcomes of all patients with SMR undergoing the MitraClip procedure in the EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) Investigational Device Exemption program, which is comprised of the randomized clinical trial, the prospective High-Risk Registry, and the REALISM Continued Access Registry (Multicenter Study of the MitraClip System).
Methods: Patients with 3 /4 SMR enrolled in EVEREST II were stratified by non-high surgical risk (non-HR) and high surgical risk (HR) status (defined as Society of Thoracic Surgeons risk of mortality >=12% or predefined risk factors). Clinical, echocardiographic, and functional outcomes at 1 year were evaluated.
Results: A total of 616 patients (482 HR, 134 non-HR; mean age, 73.3 /-10.5 years; Society of Thoracic Surgeons risk, 10.2 /-6.9%) with SMR underwent the MitraClip procedure. At baseline, 80.5% of patients were in New York Heart Association class III/IV. Major adverse events at 30 days included death (3.6%), stroke (2.3%), and renal failure (1.5%). At discharge, 88.8% had MR <=2 . At 1 year, there were 139 deaths, and the Kaplan-Meier estimate of freedom from mortality was 76.8%. The majority of surviving patients (84.7%) remained with MR <=2 and New York Heart Association class I/II (83.0%). Kaplan-Meier survival at 1 year was 74.1% in HR patients and 86.4% in non-HR patients (P=0.0175). At 1 year, both groups achieved comparable MR reduction (MR <=2 , 84.0% versus 87.0%) and improvement in left ventricular end-diastolic volume (-8.0 mL versus -12.7 mL), whereas New York Heart Association class I/II was found in 80.1% versus 91.8% (P=0.008) of HR and non-HR patients, respectively. In HR patients, the annualized rate of heart failure hospitalizations decreased from 0.68 to 0.46 in the 12 months before to 12 months after the procedure (P<0.0001).
Conclusions: Transcatheter mitral valve repair with the MitraClip in patients with secondary MR is associated with acceptable safety, reduction of MR severity, symptom improvement, and positive ventricular remodeling.
Clinical Trial Registration: https://www.clinicaltrials.gov. Unique identifiers: NCT00209274, NCT01940120, and NCT01931956.
(C) 2019 by the American College of Cardiology Foundation and the American Heart Association, Inc.